Press Coverage

FDA Clearance for Cellvizio + Pafolacianine for Molecular Imaging

9 May 2022

The US FDA has granted 510(k) clearance (K220477) for the use of the Cellvizio 100 Series platform with a molecular imaging agent called Pafolacianine (Cytalux) for real-time in vivo visualization during endoscopic, laparoscopic, and needle-based procedures, according to Mauna Kea Technologies.

Latest News

Mauna Kea Technologies Announces 2025 Half-Year Results 

Mauna Kea Technologies Announces 2025 Half-Year Results 

Mauna Kea Technologies Presents the Final Terms of its Safeguard Plan

Mauna Kea Technologies Presents the Final Terms of its Safeguard Plan

Mauna Kea Technologies and Endotherapeutics Announce Cellvizio® First Australian Orders, Advancing CellTolerance® Commercial Expansion 

Mauna Kea Technologies and Endotherapeutics Announce Cellvizio® First Australian Orders, Advancing CellTolerance® Commercial Expansion 

No results found.